Long-Term Debt (Annual)

Long-Term Debt: The sum of all long term debt fields.

Heron Therapeutics, Inc. (HRTX) had Long-Term Debt of $173.75M for the most recently reported fiscal year, ending 2023-12-31.

Quarterly Annual

Figures for fiscal year ending 2023-12-31

Income Statement Financials
Revenue	$127.04M
Net Income	$-110.56M
Cost of Goods Sold	$65.11M
Gross Profit	$61.94M
Operating Expenses	$237.66M
Operating Income	$-110.61M
Non-Operating Income/Expense	$0.06M
Pre-Tax Income	$-110.56M
Normalized Pre-Tax Income	$-110.56M
Income after Taxes	$-110.56M
Income from Continuous Operations	$-110.56M
Consolidated Net Income/Loss	$-110.56M
Normalized Income after Taxes	$-110.56M
EBIT	$-110.61M
EBITDA	$-109.12M
Weighted-Average Shares Outstanding (Basic)	138.13M
Weighted-Average Shares Outstanding (Diluted)	138.13M
Earnings per Share (EPS) (Basic)	$-0.80
Earnings per Share (EPS) (Diluted)	$-0.80
Balance Sheet Financials
Current Assets	$188.77M
Property, Plant, and Equipment	$20.17M
Long-Term Assets	$33.73M
Total Assets	$222.51M
Current Liabilities	$79.69M
Long-Term Debt	$173.75M
Long-Term Liabilities	$176.79M
Total Liabilities	$256.48M
Common Equity	$-33.97M
Tangible Shareholders Equity	$-33.97M
Shareholders Equity	$-33.97M
Common Shares Outstanding	150.28M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-58.79M
Cash Flow from Investing Activities	$18.00M
Cash Flow from Financial Activities	$54.11M
Beginning Cash	$15.36M
End Cash	$28.68M
Increase/Decrease in Cash	$13.31M
Stock-Based Compensation	$32.85M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.37
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.24
Debt to Equity Ratio	-5.11
Gross Margin	48.75%
Operating Margin	-87.07%
EBIT Margin	-87.07%
EBITDA Margin	-85.89%
Pre-Tax Profit Margin	-87.02%
Profit Margin	-87.02%
Free Cash Flow	$-60.32M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.57
Inventory Turnover	1.55
Receiveable Turnover	2.11
Days Sales in Receivables	172.77
Return on Equity	325.43%
Return on Tangible Equity	325.43%
Return on Assets	-49.69%
Return on Investments	-79.09%
Book Value Per Share	$-0.23
Free Cash Flow per Share	$-0.44
Operating Cash Flow per Share	$-0.43

Data from Zacks Investment Research, Inc.